Checkpoint immunotherapy is associated with preferential activation of tumor antigen–specific CD4+ T cells in MDS by Elizabeth A. Griffiths, Pragya Srivastava, Eduardo Cortes Gomez, Junko Matsuzaki, Kunle Odunsi, Laura W. Dillon, Devdeep Mukherjee, Christopher S. Hourigan, Jacqueline Peng, Shovik Bandyopadhyay, Kai Tan, Kristopher M. Attwood, Joseph B. Kuechle, Prashant K. Singh, Jianmin Wang, Michael J. Nemeth

Get full text

Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia by Athalia R. Pyzer, Laura W. Dillon, Elad Sharon, Theodore G. Karrison, Yuanyuan Zha, Noreen Fulton, Gege Gui, Georgia Andrew, Howard Streicher, Kendra Sweet, George Yaghmour, Jane Jijun Liu, Brian A. Jonas, Aaron D. Schimmer, Steven Grant, Amer M. Zeidan, Gerhard C. Hildebrandt, Christopher H. Lowrey, Ryan J. Mattison, Neil Palmisiano, Amandeep Salhotra, Dimitrios Tzachanis, Maria R. Baer, Tara L. Lin, Prapti Patel, Helen Chen, Walter M. Stadler, Olatoyosi Odenike, Richard A. Larson, Thomas F. Gajewski, Christopher S. Hourigan, Wendy Stock, Hongtao Liu

Get full text